Humacyte, Inc.

NASDAQ:HUMA

1.41 (USD) • At close May 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202420232022202120202019
Revenue 001.5651.2631.4916.187
Cost of Revenue 076.558.2550.0498.43275.603
Gross Profit 0-76.55-6.691.214-6.941-69.416
Gross Profit Ratio 00-4.2750.961-4.655-11.22
Reseach & Development Expenses 88.59976.5563.2661.34154.07875.603
General & Administrative Expenses 25.79923.39222.88321.1312.01316.275
Selling & Marketing Expenses 0-3.0020000
SG&A 25.79920.3922.88321.1312.01316.275
Other Expenses 0-73.443-1.565-1.263-1.4910
Operating Expenses 114.39823.49784.57881.20864.616.275
Operating Income -114.398-100.047-84.578-81.208-64.6-85.691
Operating Income Ratio 00-54.043-64.298-43.327-13.85
Total Other Income Expenses Net 0-10.72972.61354.731-1.9240.269
Income Before Tax 0-110.776-11.965-26.477-66.524-85.422
Income Before Tax Ratio 00-7.645-20.964-44.617-13.807
Income Tax Expense 00-76.184-64.0132.2020
Net Income 0-110.77664.21937.536-68.726-85.422
Net Income Ratio 0041.03529.72-46.094-13.807
EPS -1.26-1.070.620.94-5.52-4.25
EPS Diluted -1.26-1.070.620.94-5.52-4.25
EBITDA -114.398-96.4582.49-72.967-56.249-78.942
EBITDA Ratio 001.591-57.773-37.726-12.759